Zenitar

About Zenitar

Chengdu Xiuling Biomedical Technology, operating as Zenitar, is a clinical-stage biotechnology company founded in April 2019 by Chen Lijuan. Headquartered in Chengdu, China, the firm specializes in the discovery and development of innovative small molecule drugs, primarily targeting oncology, immunology, and inflammatory diseases. Zenitar has built an end-to-end drug research and development platform that integrates several advanced technologies. This includes a structural biology platform, an AI-driven drug design platform, an organoids platform for drug screening, and a patient-derived tumor model (PDOX) for evaluating efficacy.

The company's business model focuses on creating a pipeline of first-in-class or best-in-class drug candidates to address unmet medical needs. Its revenue generation is anticipated through the commercialization of its developed therapies following successful clinical trials and regulatory approvals. Zenitar has a robust pipeline with multiple assets in clinical development. Key candidates include Purinostat mesylate, a dual mTOR and HDAC1 inhibitor for various cancers, and Flonoltinib maleate, a JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms. Purinostat is advancing to Phase III trials for lymphoma after showing a high objective response rate in Phase II. Flonoltinib has shown significant spleen volume reduction in myelofibrosis patients.

Since its inception, Zenitar has achieved significant financial milestones, raising a total of $108 million. The company secured a Series B+ funding round of approximately $56 million (RMB 400 million) in August 2025, led by Qiming Venture Partners, to advance its late-stage clinical candidates and support global expansion plans. Other notable investors include 5Y Capital, Jifeng Ventures, and LYFE Capital. The company holds a strong intellectual property portfolio with 34 patents, 17 of which are international, and has received 19 Investigational New Drug (IND) approvals from authorities in China and the US. Zenitar plans to initiate multinational Phase III studies for two of its candidates in 2025 as part of its global expansion strategy.